Research and development daily Imfinzi first-line treatment of extensive stage small cell lung cancer has been approved by the European Union

2020.09.02 Research and Development NEWS: Consino Bio-New Crown Vaccine Enters Phase III Clinical Trials; Acasti's Treatment of SHTG Candidate Drugs Another Phase 3 Clinical Failure; Innovative Oral Yew Alcohol Formula Approved by FDA Priority Review for Treatment of Metastylated Breast Cancer ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) Acasti's treatment of sHTG candidate drugs another Phase 3 clinical failure Acasti Pharma announced in January this year the company's treatment of SHTG candidate drug CaPre Phase 3 clinical trial failure, the company on August 31 announced another Phase 3 clinical study TRILOGY 2 results, CaPre has not reached the main endpoint.
Concino Bio-New Coronary Vaccine entered Phase III clinical trials on Tuesday, Concino Bio announced that it has begun reorganizing Phase III clinical trials of the new coronavirus vaccine (Adenovirus Type 5 vector) ("Ad5-nCoV").
Hundred Times Zeposia Treatment of Multiple Sclerosis has long-term efficacy and safety BMS recently unveiled a new drug for multiple sclerosis at the 8th Joint ACTRIMS-ECTRIMS Conference of MSVirtual2020 The interim results of the Zeposia 3 Open Label Extension Trial DAYBREAK confirmed Zeposia's long-term efficacy and safety in patients with multiple sclerosis: most patients did not relapse during the 24th and 36th months of treatment and did not have new safety issues.
Drug Approval: AstraZeneca Imfinzi's first-line treatment of broad-stage small cell lung cancer was approved by the European Union, AstraZeneca announced that Imfinzi combined etoposide and carpentin or cisplatin for first-line treatment of adults with broad-stage small cell lung cancer was approved by the European Commission for listing.
Extended First Full Remission AML Patient Life FDA approved the first continuous treatment BMS announced today that the FDA has approved the listing of Onureg, developed by the company, as a continuation treatment for adult acute myeloid leukemia (AML) patients who receive their first complete remission (CR) or CR with incomplete blood cell count after strong induced chemotherapy.
Innovative oral yew alcohol formula was approved by the FDA for priority review for the treatment of metastasis breast cancer Today, Athenex announced that the FDA has accepted the company's application for a new drug for oral yew alcohol and granted it priority review eligibility for metastasis breast cancer.
THE FDA expects to respond by February 28 next year.
and Nord Sogroya are FDA-approved: the first weekly subdern injection of growth hormone FDA recently approved Noor and Nord's weekly long-acting growth hormone derivative Sogroya for adult treatment of growth hormone deficiency (GHD).
it's worth noting that Sogroya is the first human growth hormone (hGH) therapy to be injected only once a week in adult GHD, while other FDA-approved hGH preparations must be injected daily.
China biopharmaceutical breast cancer drug "Fluvis Group Injection" by the drug registration certificate 1, China Biopharmaceutical announced that the group developed the treatment of breast cancer drug "Fluvis Group Injection" (commodity name: Qingcoyi) has been issued by the State Drug Administration drug registration certificate, the first approval of the variety, and as the same through generic quality and efficacy consistent evaluation.
Bibet Pharma another new drug approved clinical CDE latest publicity, by Bibet Pharmaceutical Technology Team and Cynthambet Pharmaceuticals jointly developed innovative class 1 new drug ZXBT-1158 capsules obtained two clinical trials implied license, intended to develop for the treatment of late-stage recurrence difficult to treat B cell malignancies.
the FDA has accepted three new drug applications from Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko (tezacaftor/ivacaftor andivacaftor), and Kalydevacco (iacaftor), according to a recent announcement by the FDA.
Qilu Pharmaceuticals "Malay acid afatini tablets" will be approved recently, Qilu Pharmaceuticals "Malay acid afatini tablets" listing application changed to "in the approval", is expected to be approved for the market in the near future, Qilu will become the second approved for listing of pharmaceutical companies.
Health yuan isopropyl bromide inhalation solution 4 generic drugs were approved in recent days, health yuan subsidiary Shenzhen Mrs. Pharmaceuticals isopropyl tobly bromide inhalation solution 4 generic listing applications entered the "in the approval" stage, will soon usher in good news.